Research use only. Read more

Anti-inflammatory

GLOW (25/5/5)

A three-peptide skin and connective-tissue blend leading with GHK-Cu and supplemented with BPC-157 and TB-500; investigated for combined dermal and systemic healing research.

Quick facts

Molecular weight

340 Da

Half-life

1 h

Frequency

daily

Admins / wk

7

Routes

SubQ

Typical dose

1.00 mg–3.00 mg

Mechanism & positioning

A three-peptide skin and connective-tissue blend leading with GHK-Cu and supplemented with BPC-157 and TB-500; investigated for combined dermal and systemic healing research.

Researched for: skin regeneration, connective-tissue repair.

Blend composition

ComponentMass in vial% of blend
GHK-Cu25 mg71.4%Profile
BPC-1575 mg14.3%Profile
TB-5005 mg14.3%Profile

Reconstitution defaults

Default vial

35 mg

BAC water

3 mL

Concentration

11667 mcg/mL

Doses per vial

~35

Calculate with this peptide

Related peptides in the Anti-inflammatory class

Frequently asked questions about GLOW (25/5/5)

What is the typical research dose range for GLOW (25/5/5)?
GLOW (25/5/5) is most commonly investigated at 1.00 mg–3.00 mg per administration, daily. Note: per GHK-Cu component. These values reflect documented research-stage protocols and are not medical recommendations.
What is the half-life of GLOW (25/5/5)?
GLOW (25/5/5) has an approximate plasma half-life of 1 hours. Practical steady state is reached after roughly five half-lives — about 0 days under continuous administration.
How is GLOW (25/5/5) administered in research protocols?
Published research uses subq administration. Typical reconstitution is 35 mg vial in 3 mL of bacteriostatic water, producing a concentration of 11667 mcg/mL.
What vial sizes are commonly available for GLOW (25/5/5)?
Common stocked vial sizes are 35 mg. The 35 mg vial is the most-used default in published protocols.